Amicus Therapeutics (NASDAQ:FOLD) Share Price Passes Above 200 Day Moving Average – Should You Sell?

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $9.78 and traded as high as $14.29. Amicus Therapeutics shares last traded at $14.28, with a volume of 4,435,961 shares traded.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Needham & Company LLC lowered shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, December 19th. Citigroup reiterated a “neutral” rating and set a $14.50 price objective (down previously from $17.00) on shares of Amicus Therapeutics in a report on Monday, December 22nd. JPMorgan Chase & Co. increased their price objective on shares of Amicus Therapeutics from $18.00 to $19.00 and gave the stock an “overweight” rating in a research report on Thursday, November 6th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $14.50 target price (down from $16.00) on shares of Amicus Therapeutics in a research report on Thursday, January 22nd. Finally, The Goldman Sachs Group increased their price target on Amicus Therapeutics from $9.00 to $11.00 and gave the stock a “neutral” rating in a report on Wednesday, November 5th. Four investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $15.55.

Amicus Therapeutics Price Performance

The stock has a market capitalization of $4.48 billion, a P/E ratio of -356.91 and a beta of 0.38. The business’s 50 day simple moving average is $13.05 and its two-hundred day simple moving average is $9.78. The company has a quick ratio of 2.09, a current ratio of 2.99 and a debt-to-equity ratio of 1.70.

Amicus Therapeutics (NASDAQ:FOLD) last posted its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.17 earnings per share for the quarter, topping analysts’ consensus estimates of $0.12 by $0.05. The company had revenue of $169.06 million for the quarter, compared to analyst estimates of $165.24 million. Amicus Therapeutics had a negative net margin of 2.35% and a positive return on equity of 6.95%. The firm’s revenue was up 19.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.10 EPS. As a group, sell-side analysts forecast that Amicus Therapeutics, Inc. will post 0.15 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Amicus Therapeutics news, insider Jeff Castelli sold 76,158 shares of Amicus Therapeutics stock in a transaction on Monday, November 24th. The shares were sold at an average price of $10.16, for a total transaction of $773,765.28. Following the transaction, the insider directly owned 439,318 shares of the company’s stock, valued at $4,463,470.88. The trade was a 14.77% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider David Michael Clark sold 25,643 shares of the company’s stock in a transaction on Monday, November 24th. The stock was sold at an average price of $10.10, for a total transaction of $258,994.30. Following the completion of the sale, the insider owned 296,975 shares of the company’s stock, valued at approximately $2,999,447.50. The trade was a 7.95% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 394,807 shares of company stock worth $4,486,385 in the last ninety days. Corporate insiders own 2.20% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in FOLD. Vestal Point Capital LP raised its stake in Amicus Therapeutics by 178.4% in the 2nd quarter. Vestal Point Capital LP now owns 11,900,000 shares of the biopharmaceutical company’s stock valued at $68,187,000 after acquiring an additional 7,625,000 shares during the period. UBS Group AG grew its stake in Amicus Therapeutics by 240.5% in the 4th quarter. UBS Group AG now owns 5,893,288 shares of the biopharmaceutical company’s stock valued at $83,920,000 after buying an additional 4,162,433 shares in the last quarter. Norges Bank bought a new stake in Amicus Therapeutics during the 2nd quarter valued at $18,540,000. Qube Research & Technologies Ltd lifted its position in shares of Amicus Therapeutics by 223.9% during the second quarter. Qube Research & Technologies Ltd now owns 3,466,911 shares of the biopharmaceutical company’s stock worth $19,865,000 after acquiring an additional 2,396,410 shares in the last quarter. Finally, State Street Corp lifted its position in shares of Amicus Therapeutics by 21.5% during the second quarter. State Street Corp now owns 11,568,097 shares of the biopharmaceutical company’s stock worth $66,285,000 after acquiring an additional 2,049,078 shares in the last quarter.

About Amicus Therapeutics

Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company’s lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.